Edition:
United Kingdom

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

16.21USD
18 Apr 2019
Change (% chg)

$-0.14 (-0.86%)
Prev Close
$16.35
Open
$16.40
Day's High
$16.57
Day's Low
$15.79
Volume
148,037
Avg. Vol
334,682
52-wk High
$32.32
52-wk Low
$9.87

Latest Key Developments (Source: Significant Developments)

MacroGenics Announces Removal Of Partial Clinical Hold On MGD009 Program By FDA
Friday, 25 Jan 2019 

Jan 25 (Reuters) - MacroGenics Inc ::MACROGENICS ANNOUNCES REMOVAL OF PARTIAL CLINICAL HOLD ON MGD009 PROGRAM BY FDA.MACROGENICS INC - DURING PARTIAL HOLD, COMPLETED ENROLLMENT OF FIRST DOSE ESCALATION COHORT FOR MGC018, OUR B7-H3-TARGETED ADC.MACROGENICS - ENROLLMENT OF NEW PATIENTS IN U.S. HAS BEEN CLEARED TO PROCEED WITH PHASE 1 MONOTHERAPY AND COMBINATION STUDIES OF MGD009.MACROGENICS INC - THE PARTIAL CLINICAL HOLD DID NOT INVOLVE OTHER B7-H3 PROGRAMS.  Full Article

Trianni, Inc. And Macrogenics, Inc. Announce License Agreement
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - MacroGenics Inc ::TRIANNI, INC. AND MACROGENICS, INC. ANNOUNCE LICENSE AGREEMENT.MACROGENICS INC - NO FINANCIAL DETAILS WERE DISCLOSED..MACROGENICS INC - NO FINANCIAL DETAILS WERE DISCLOSED.  Full Article

NanoString Technologies Says Enters Translational Research Collaboration With MacroGenics To Identify And Develop Biomarkers In Immuno-Oncology
Monday, 29 Oct 2018 

Oct 29 (Reuters) - MacroGenics Inc ::MACROGENICS AND NANOSTRING ENTER TRANSLATIONAL RESEARCH COLLABORATION TO IDENTIFY AND DEVELOP BIOMARKERS IN IMMUNO-ONCOLOGY.NANOSTRING TECHNOLOGIES INC - CO, MACROGENICS ENTERED AGREEMENT TO IDENTIFY AND DEVELOP BIOMARKERS FOR MACROGENICS' MGD013 PROGRAM.NANOSTRING TECHNOLOGIES INC - WILL DEVELOP, EVALUATE TUMOR INFLAMMATION SIGNATURE AND NOVEL PREDICTIVE GENE EXPRESSION SIGNATURES FOR MGD013.  Full Article

Macrogenics Inc Prices Of Public Offering
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Macrogenics Inc ::MACROGENICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.50 MILLION COMMON SHARES PRICED AT $21.25PER SHARE.  Full Article

Macrogenics Announces Proposed Public Offering Of Common Stock
Monday, 26 Mar 2018 

March 26 (Reuters) - Macrogenics Inc ::MACROGENICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 4.50 MILLION COMMON SHARES.  Full Article

Macrogenics Enters Research Collaboration With Roche
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Macrogenics Inc ::MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE.MACROGENICS INC - UNDER TERMS OF AGREEMENT, ROCHE WILL PAY MACROGENICS AN UPFRONT PAYMENT OF $10 MILLION.MACROGENICS INC - MACROGENICS WILL ALSO BE ELIGIBLE TO RECEIVE UP TO $370 MILLION IN POTENTIAL MILESTONE PAYMENTS AND ROYALTIES ON FUTURE SALES.MACROGENICS INC - FURTHER DETAILS ABOUT TRANSACTION ARE NOT DISCLOSED.MACROGENICS INC - ENTERED INTO A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC..  Full Article

Incyte and MacroGenics announce global collaboration and licensing agreement
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Incyte Corp :Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012.MacroGenics inc - ‍Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications​.MacroGenics Inc - ‍upon closing, Incyte will pay MacroGenics an upfront payment of $150 million​.MacroGenics - ‍co is eligible to receive up to $420 million in potential development, regulatory milestones, up to $330 million in potential commercial milestones​.MacroGenics Inc - ‍MacroGenics retains right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012​.MacroGenics Inc - ‍MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018​.MacroGenics - ‍if MGA012 approved & commercialized, co will be eligible to get royalties, tiered from 15 percent to 24 percent, on future sales by Incyte​.  Full Article

IFR Americas ECM Pipeline

Genpact (US, BPO) – $324m Block. 10m shares (100% sec) at $32.40 versus $32.40-$32.62 marketing and $32.62 last sale. GS.